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1. Introduction 
The polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women 
of reproductive age [1]. PCOS is not only accompanied with negative physical 
consequences, but this syndrome also affects psycho-social and sexual well-being. 
Characteristics of PCOS include enlarged ovaries with a polycystic appearance along with 
menstrual irregularities such as amenorrhoea or oligoamenorrhoea, excessive growth of 
body hair (hirsutism) or biochemical hyperandrogenism, and to a lesser extent acne. In 
addition, PCOS is associated with anovulatory infertility, obesity, insulin resistance, and 
lipid disorders [2, 3]. 
In clinical scenarios, the treatment of women with PCOS is mainly focused on correcting 
menstrual disturbances and physical consequences. Besides the physical consequences, the 
negative implications of PCOS in daily life such as impaired social contacts and sexual 
satisfaction and depression seem to be rarely discussed with PCOS women during 
treatment. The scientific interest in the psycho-social and sexual consequences of PCOS has 
grown in the past years and has increased our knowledge on these topics. For example, 
recent studies indicated that PCOS is associated with depression [4-6], body dissatisfaction 
[5, 6], decreased quality of life [7], a decreased feeling of sexual attractiveness and self-
esteem as well as sexual dissatisfaction [4, 7]. 
First, an extensive overview is provided in this chapter on what is known about psycho-
social and sexual well-being in women with PCOS (Part I). Second, we studied the 
association between on the one hand common physical features of PCOS (polycystic ovaries, 
hirsutism, acne, menstrual irregularities, and Body Mass Index) and endocrine variables 
(e.g. testosterone, progesterone, and estradiol) and sexual well-being on the other hand (Part 
II). In addition, we evaluated whether there is an association between aspects of psycho-
social well-being (self-esteem, body satisfaction, and self-perceived fear of negative 
appearance evaluation) and sexual well-being (Part II). 
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2. Part I: Psycho-social well-being in women with PCOS 
In some women, the appearance of PCOS might be characterized by an excess growth of body 
hair on various body areas such as the chin, lip, abdomen, and arms as well as by acne. It is 
imaginable that these outer appearances, together with non-visible characteristics (e.g. 
menstrual irregularities) influence psycho-social well-being. Moreover, PCOS causes infertility 
and involuntary childlessness. It has in fact been shown that women with PCOS report more 
psychological distress than controls [7, 8]. With respect to the diagnosis of PCOS itself, one 
study measuring patient’s perception of the diagnosis of PCOS found that the emotions 
associated with the diagnosis included frustration (67%), anxiety (16%), and sadness (10%) [9].  
It has been shown that hirsutism, menstrual irregularities, and infertility are the PCOS 
symptoms experienced as most bothersome by affected women [10]. Lipton and colleagues 
[11] demonstrated that women with facial hair spend a considerable time on the 
management of their facial hair (104 min/week). Besides, two thirds reported continually 
checking their facial hair in mirrors and 76% by touch. In addition, more than half of the 
women tried at least four methods for hair removal in the past. Furthermore, it is 
conceivable that infertility increases a woman’s emotional distress. Indeed, many PCOS 
women seem to worry about remaining without children in the future and report a current 
wish to conceive; however, infertility does not appear to be a determinant for psychological 
problems [12]. Together, it is imaginable that the symptoms of PCOS might cause a woman 
to experience issues with their femininity and might therefore not only affect psychological 
well-being, but more in particular sexual well-being. Studies have indicated that women 
with PCOS experience more psychological problems such as depression and anxiety than 
non-PCOS controls with infertility problems [13], indicating that mood swings might be 
caused by the distressing symptoms of the syndrome. The emotional distress related to 
symptoms and consequences of PCOS might affect various domains of their lives, including 
romantic relationships, friendships, social contacts, and their working life. It could be that 
women find it difficult to share their experiences with other people and feel uncomfortable 
when conversations about motherhood are started. Also, about 50% of all women with 
PCOS are overweight, compared to 30% of women in the general population [2]. A higher 
Body Mass Index (BMI) in women with PCOS is not only related to negative physical [2, 3, 
14, 15], but also to negative psychological consequences [4].  
Altogether, a greater incidence of psychological problems have been found in women with 
PCOS [8]. In the sections below we will describe what is known about psycho-social well-
being in women with PCOS as well as the association with features of PCOS. The results 
will not be discussed in detail as this is beyond the scope of this chapter.  
2.1 Quality of Life 
It is widely recognized that QoL is significantly reduced in women with PCOS [6, 16-18]. 
Generic QoL (focuses on domains of well-being in general) [19, 20] as well as specific QoL 
(focuses on domains of well-being related to a specific disease/syndrome) measurements 
[21] are used in research. Several studies investigated mechanisms that might be responsible 
for a reduced QoL in PCOS women. Being overweight has been found to be one of the most 
important contributors reducing QOL in women with PCOS [7, 22, 23]. In addition, there is 
converging evidence suggesting that hirsutism is one of the most important predictors of 
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impaired QoL besides obesity [4, 23, 24]. In addition, it is demonstrated that acne, diabetes 
mellitus [21], menstrual irregularities [7], and concerns about infertility [4, 25, 26] are related 
to a reduced QoL in women with PCOS. Nevertheless, Hahn et al. [23] failed to find an 
association between QoL and androgens and insulin resistance.  
With respect to psychological mechanisms, a reduced psychological QoL in PCOS women 
has been indicated to be associated with a passive coping style (a maladaptive coping 
strategy) [16] as well as with anxiety and depression [27].  
2.2 Depression 
Women with PCOS report higher levels of depressive symptoms than the general 
population [8]. The prevalence of depressive symptoms is not only higher but also more 
variable (25-64%) [12, 28-31] than for women in the general population. In addition, it has 
been found that women with PCOS report higher depression scores than non-PCOS controls 
with fertility problems [13]. PCOS features, endocrine imbalance (e.g. testosterone levels), 
and psychological mechanisms seem to have an impact on mood in women with PCOS and 
have therefore been studied as mediators of depression. For example, infertility [12] and an 
unfulfilled wish to conceive [27] do not appear to contribute to higher depression scores; 
however, infertile PCOS women seem to have higher depression scores compared to 
infertile women in whom infertility is related to other causes than PCOS [5]. Hence, other 
characteristics of PCOS seem to play a mediating role. Several studies have shown that BMI 
is related to depressive symptoms [22, 32, 33] as well as hirsutism and acne [11, 27]. 
Moreover, higher depression scores have been demonstrated in PCOS women with 
hirsutism compared to women with newly diagnosed gynaecological cancer [34].  
PCOS is associated with high testosterone levels. Lower testosterone levels seem to be 
related to depression in women with PCOS [35]. Also, testosterone was found to be lower in 
depressive PCOS women compared to PCOS women without depressive symptoms, 
whereas the researchers found no significant relation between BMI and hirsutism [36]. 
Conversely, Barry and colleagues [13] failed to find an association between testosterone and 
mood disturbances in women with PCOS. Accordingly, others failed to find an association 
between depression and hormonal and metabolic profile [36, 37]. 
With respect to psychological mechanisms, it has been shown that depression in PCOS 
women is predicted by a poorer perception of self-worth and body image [29, 38], fitness 
orientation, appearance evaluation, lower QoL [29], and passive coping style (a maladaptive 
coping strategy) [16]. 
2.3 Anxiety and fears 
Recently, researchers showed an increased level of anxiety [27, 29] and social anxiety [8] in 
PCOS women compared to controls. The finding of reduced sleep in women with PCOS 
might be explained by a higher prevalence of sleep apnea in obese women with PCOS [39].  
An interesting issue is determining which characteristics of PCOS are related to anxiety. It 
has been shown that not only visual features of PCOS such as a higher body weight and an 
excessive growth of bodily hair were related to an increased experience of fear of what other 
people thought about their appearance, but also the absence of their cycle (amenorrhoea) 
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was negatively associated with fear of appearance evaluation [40]. The association between 
fear of negative appearance evaluation and non-visual characteristics might be explained by 
a reduced feeling of femininity [10]. The experience of women with PCOS feeling less 
feminine seem to be related to menstrual irregularities and hirsutism [10]. Contrasting 
findings have been found with respect to the relation between anxiety and hirsutism. Some 
studies reported women with hirsutism showing greater anxiety levels [7, 11] and social 
fears [41]. Moreover, one study found that higher anxiety scores were indicated in PCOS 
women with hirsutism than in women with newly diagnosed gynaecological cancer [34]. 
Furthermore, both acne and an unfulfilled wish to conceive seem to be a risk factor for 
clinically relevant anxiety in women with PCOS [27]; however, this study failed to find a 
relationship for BMI and hirsutism. This is in the same line with other study results not 
finding a relationship between anxiety, acne, hirsutism, and BMI [36, 42]. Contrasting 
findings might be explained by the use of different questionnaires. 
Livadas et al. [36] studied whether anxiety was associated with hormonal and metabolic 
profile. PCOS women with higher anxiety scores showed significantly elevated HOMA-IR 
(insulin resistance) and FAI (free androgen excess) values than PCOS women with lower 
anxiety scores, independently of BMI; however, no relation was found with hormonal values 
such as testosterone, androstenedione, sex hormone-binding globulin levels, 
dehydroepiandrosterone sulphate, and estradiol. In the same line, the relation between greater 
FAI values and greater levels of anxiety was previously reported by Mansson et al. [8]. 
Moreover, Deeks and colleagues [29] indicated in a cross-sectional study in PCOS women 
and controls that poor perception of self-worth and body image as well as health evaluation 
predicted higher anxiety levels. It has also been found that anxiety in PCOS women is 
associated with having a passive coping style [16].  
2.4 Self-esteem and body satisfaction 
A recent study demonstrated a more negative body image in women with PCOS 
compared to healthy controls [29]. It has been indicated that women with facial hair and 
decreased self-esteem have higher depression and anxiety scores as well as poorer QoL 
[11], although poorer self-esteem compared to the general population was not confirmed. 
In a previous study, we showed that women with PCOS and a higher BMI in addition to 
hirsutism reported having poorer self-esteem and greater body dissatisfaction than 
women without hirsutism and lower BMI scores. In addition, amenorrhoea was 
associated with poorer self-esteem whereas hyperandrogenism and acne were found to be 
associated with body dissatisfaction. In line with our previous findings, it has been shown 
that women with PCOS and clinical symptoms of hirsutism and acne have greater body 
dissatisfaction than healthy controls with regular cycles, even after adjustment for BMI [5, 
35]. Furthermore, poorer self-esteem in PCOS women has been linked to higher levels of 
depression and anxiety [29, 38]. 
2.5 Other domains of psycho-social well-being 
2.5.1 Eating disorders 
A higher prevalence of eating disorders such as bulimia has been reported in women with 
PCOS compared to controls [8]. One study found that 12.6% of PCOS women had an eating 
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disorder compared to 1.6% in controls [32]. No association between PCOS characteristics 
(such as hirsutism and acne) and eating disorders has been found [43]. Further, Livadas and 
colleagues [36] failed to find an association between eating disorders and hormonal and 
metabolic profile in women with PCOS. 
2.5.2 Suicide 
Mansson et al. [8] were the first who studied suicide attempts in women with PCOS: they 
found that suicide attempts were seven times more common in women with PCOS 
compared to controls [8]. This finding might be explained by the increased risk for 
psychological disturbances such as depression and anxiety. 
2.5.3 Neuroticism and stress responses 
Furthermore, a recent study reported that women with PCOS were more neurotic, meaning 
that they had difficulties coping with stress, exhibited more anger symptoms, and were 
more likely to withhold feelings of anger compared to non-PCOS women with fertility 
problems [44]; however, these findings disappeared with using multiple regression 
analyses, indicating that they might be related to distressing symptoms of the syndrome. In 
addition, disturbed stress responses were indicated in PCOS women [45]. This finding 
might be linked to the elevated risks for depression, overweight, and the cardiovascular and 
diabetes risks associated with the diagnosis 
3. Sexual well-being in women with PCOS 
Hormones play a major role in various aspects of sexuality. As PCOS is an endocrine 
disorder, it seems plausible that the endocrine changes associated with PCOS influence 
sexuality. Sexuality is an important aspect of an individual’s well-being, highlighting the 
importance of our understanding of sexuality in women with PCOS. Existing studies with 
respect to PCOS and sexuality have been mainly focussing on sexual satisfaction in women 
with PCOS, whereas for example sexual functioning has not been given much attention. 
Sexual satisfaction is defined as the balance between costs and rewards concerning sexuality 
[46], for example: A woman without problems in the domain of sexual desire but who 
experiences painful intercourse has lowered sexual satisfaction because the costs (pain) are 
too high. Sexual functioning refers to the ability to experience the phases of the sexual 
response cycle (desire, arousal, lubrication, orgasm), for example: A woman who is able to 
feel sexually aroused but who is not able to experience an orgasm has poorer sexual 
functioning. Sexual satisfaction is part of sexual functioning [47] given that a person without 
problems in the domain of sexual functioning might experience a decreased sexual 
satisfaction, for example caused by negative feelings such as guilt. On the contrary, not 
being able to function sexual fully does not necessarily mean that one has low sexual 
satisfaction; one might not experience this as a problem. It is imaginable that clinicians and 
researchers find it more comfortable talking about sexual satisfaction than sexual 
functioning, with the latter being more detailed and intimate. Clinicians might not be 
trained in discussing sexual problems with their patients or it is unknown as to where to 
refer patients to with sexual problems.  
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3.1 Sexual functioning in women in general: The role of hormones 
Androgens and estrogens play an important role in female sexual functioning. The sex 
steroids testosterone and estradiol play a role in all structures and organs related to female 
sexual functioning. For example, changes in sexual desire are noticed during changes in the 
menstrual cycle [48]. Sexual desire refers to a subjective feeling that is triggered by both 
internal and external cues, which may or may not result in overt sexual behaviour [49]. 
Sexual arousal has physiological and subjective aspects: the physiological part is related to 
an increased autonomic activation that prepares the body for sexual activity and increases 
the amount of sexual stimulation necessary to induce orgasm. The subjective part is related 
to an emotional state of arousal, including sexual thoughts and fantasies[50].  
3.2 Estrogens 
Estrogens play an important role in making the brain susceptible for the influence of 
testosterone. In addition, estrogens influence mood and physical signs of sexual 
attractiveness (e.g. breast development). An estrogen deficiency can cause various 
complaints such as mood disturbances and might indirectly influence sexuality negatively 
[51, 52]. It has been demonstrated in healthy pre-menopausal women without PCOS that 
menstrual cycle changes can influence sexual behaviour by changes in psychological well-
being: improved sexual activity (frequency of partner sex, masturbation and orgasm) was 
related to an increased well-being (mood and pre-menstrual symptoms) [48]. 
Furthermore, atrophic changes (thinning of the vaginal walls) are influenced by reduced 
estrogen levels [53, 54]; however, sexual reactions, sexual arousal, lubrication and genital 
vasocongestion do not seem to be estrogen dependent. Even though estrogen levels were 
significantly different, studies failed to find a difference in sexual functioning between pre-
menopausal and post-menopausal women [51, 52]. Likewise, no evidence has been found 
for a significant effect of estrogen on sexual interest, arousal, and orgasmic response [48, 53]. 
The best predictor for post-menopausal sexual functioning seems to pre-menopausal sexual 
functioning [53]. Estrogen levels are in general within the normal range in women with 
PCOS [55]. 
3.3 Androgens 
Androgens have been indicated to play an important role in female sexual functioning [56] 
and seem to influence sexual desire and arousal (either alone or in combination with estrogen), 
sexual thoughts, sexual fantasies, and nocturnal genital responses [54, 57]. Androgens prepare 
the female sexual system to be susceptible for sexual stimuli and sexual arousal [54, 56]. Sexual 
arousal through non-cognitive processes (audiovisual stimulation, ‘quick and dirty’) has not 
been found to be androgen dependent, whereas sexual arousal through cognitive processes 
(thoughts, fantasies, ‘neat and slow’) has been shown to be androgen dependent [56]. 
Androgen levels are often increased in women with PCOS which in turn might influence 
sexual thoughts and desire [55]. Bancroft et al. [48] failed to find an association between 
testosterone levels and sexual activity with their partner; however, a positive relation was 
found with respect to the frequency of masturbation. Finally, testosterone and DHEAS were 
not found to be related with Hypoactive Sexual Desire Disorder (HSDD: a deficiency or 
absence of desire for sexual activity) in community based studies in women [53, 58, 59].  
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3.4 Hyperandrogenism and sexuality  
A recent publication [60] found that not only acne and hirsutism improved by oral 
contraception as a result of reduced androgen levels, a positive influence on social contacts, 
QoL, sexual self-esteem, and feelings of sexually attractiveness has also been found. In 
addition, sex life in general (sexual pleasure in particular) and orgasm by intercourse 
improved as well as that dyspareunia (painful sexual intercourse) declined. Moreover, the 
frequency of intercourse increased as opposed to the frequency of masturbation. Sexual 
functioning seems to be improved by the mediation of improved QoL, whereas sexual self-
esteem and sexual attractiveness as a result of decreasing hirsutism and acne [60]. 
Furthermore, Wierman and colleagues [53] found a minor influence of hyperandrogenism 
or its treatment on sexual functioning in women with PCOS. The researchers speculate that 
psycho-social factors such as decreased levels of self-esteem might have a greater impact on 
sexuality. 
Abovementioned studies indicate that hormonal influences play a minimal role in 
predicting sexual functioning in women with PCOS. Lowered sexual satisfaction and sexual 
functioning might be mediated by psychosocial factors or by a variety in responsiveness to 
testosterone [61]. Finally, contextual influences (e.g. partner relationship) combined with the 
appropriate stimuli can cause sexual arousal resulting in sexual desire [57, 62-64].  
4. Sexual functioning  
4.1 Sexarche and sexual intercourse 
It has been found that adolescents and women with PCOS become sexually active later in 
life than controls. In addition, it seems that PCOS women are less likely to have had 
intercourse compared to their healthy peers [7, 26, 65]. Furthermore, De Niet et al. [40] 
found that sexarche (the first sexual intercourse) is related to amenorrhoea; women with 
PCOS and amenorrhoea had an earlier sexarche than women with PCOS and 
oligomenorrhoea.  
Although it has been indicated that PCOS women experience lower sexual satisfaction and 
feel less attractive than controls, the frequency of sexual intercourse [7, 66] and the number 
of sexual partners [66] was not found to be different compared to controls. Moreover, it has 
been found that the frequency of sexual intercourse increased as a result of improved QoL, 
sexual self-esteem, feelings of sexual attractiveness, and sexual pleasure when using oral 
contraceptive [60].  
Pagidas et al. [67] found that intercourse compliance (2-3 times a week) was related to 
having an ovulatory cycle in women undergoing fertility treatment. An ovulatory cycle 
increased intercourse compliance, especially in women with a BMI over 35. 
Painful sexual intercourse has also been studied [7, 23, 60, 66]. Two studies have found that 
pain during sexual intercourse is increased in women with PCOS compared to controls [23, 
66]. The incidence of painful intercourse seems to be negatively influenced by BMI [23]. 
Painful intercourse seem to decrease with the use of oral contraceptives [60] or metformin 
[65], probably due to mediating factors of overall increased sexual functioning (in particular 
sexual pleasure).  
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4.2 Sexual desire  
Conaglen & Conaglen [68] compared women with PCOS or idiopathic hirsutism (IH) and 
healthy controls on psychosocial functioning and various aspects of sexuality including 
sexual desire. Sexual desire was found to be significantly lower in PCOS women than in 
controls. After anti-androgen medication, the treatment group reported a significantly 
further decline in sexual desire despite a significantly increase in self-esteem and a decrease 
in hirsutism. This indicates that anti-androgen therapy can improve self-esteem and 
hirsutism, but negatively influences sexual desire. This could be due to decreasing androgen 
levels causing the brain to be less susceptible to sexual stimuli resulting in decreased sexual 
desire [54]. In line with these findings, studies failed to find a relation between sexual desire 
and androgen levels [57, 58, 67] in non PCOS women; however, an impaired sexual interest 
and desire (e.g., arousal, orgasm, pain, initiation, receptiveness, affection, relationship) was 
shown in with women with HSDD compared to controls [58]. In contrast, two studies 
indicated that women with PCOS seem to take more sexual initiative and to have greater 
sexual desire than controls [66, 69]. Interestingly, one study found PCOS women reporting 
less interest in physical contact with their partner compared to controls. These contrasting 
findings might be explained by psychological factors [61]. 
4.3 Sexual arousal, orgasm 
As mentioned before, androgens influence sexual arousal; however, free or total testosterone 
has not been found to be related to arousal. Furthermore, it has been shown that women 
with PCOS are less satisfied with their sex life, had more problems with getting aroused, 
and showed more often no interest in physical contact with their partner compared with 
healthy controls [66]. In addition, insufficient lubrication was significantly higher in PCOS 
women [11]. This finding seems to explain the higher incidence of painful sexual 
intercourse.  
The incidence of sexual thoughts and fantasies (part of subjective arousal) seems to be 
negatively correlated to BMI [23]; however, orgasm frequency was not found to differ 
between PCOS women and controls [66]. In addition, total serum testosterone but not FAI 
was positively related to higher scores in aspects of sexual functioning (such as satisfaction 
sex life, frequency of orgasm during intercourse, and vaginal lubrication) in PCOS women 
[66]. A hypothesis is that levels of testosterone above average improve sexual functioning; 
however, this is not in line with other findings [12, 23, 66, 68]. 
Using oral contraceptives seem to improve the frequency of orgasm during intercourse in 
women with PCOS [60], probably due to mediating factors as improved sexual pleasure, 
sexual self-esteem, and BMI. One study [70] failed to find a difference in sexual functioning 
or in genital anatomy between lean PCOS women and lean controls. Despite differences in 
androgen levels, no difference was found in clitoral volume and vascularisation. 
4.4 Sexual satisfaction, attractiveness, and self-worth 
It is widely recognized that women with PCOS report a decreased sexual satisfaction than 
healthy controls [7, 12, 26, 65, 66]. Sexual satisfaction seems to be influenced by both 
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endocrine and psycho-social factors. For example, both BMI and hirsutism seem to 
negatively influence sexual satisfaction, sexual attractiveness [23], and body esteem [68]. 
PCOS women also thought that their partners found them less sexually attractive [12]. Using 
an oral contraceptive improved hirsutism and acne [60, 68] which led to an improved feeling 
of sexual attractiveness and sexual self-esteem [60].  
Sexual self-worth seems to be lower in PCOS women [12, 17]. This finding might be related 
to infertility; however, this association could not be established. No other studies were 
found using the term self-worth. Self-esteem was reported [60, 68] and seem to be related to 
hirsutism and acne [68, 71]. 
Furthermore, it seems that BMI, hirsutism, and acne negatively influence making social 
contacts [12, 23] in women with PCOS. This finding might be explained by lower levels of 
self-esteem and other psychosocial factors [70].  
Finally, poorer body-image has been found to be associated with sexual avoidance [38] in 
women with PCOS compared to controls. Likewise, depression as a consequence of BMI 
was also found to have a negative association with sexual functioning in pre-menopausal 
women [72]. A similar relation might be expected in women with PCOS. In the same line, 
psychosocial aspects seem to negatively influence sexuality in women with PCOS: impaired 
psychological well-being [7, 60, 68], partner relationship [47], general health [65], social 
influences [59], and quality of the sexual stimuli [47]. 
4.5 Sex-typed behaviour and sexual orientation in PCOS women 
Last, there is evidence that sex typed behaviour and sexual orientations are related to 
hormonal levels. One study measured sex-typed behaviour online as well as self-reported 
PCOS diagnosis [73]. The results indicated that PCOS women reported significantly less 
typical feminine behaviour as a child (e.g., experimenting with make-up). In addition, PCOS 
women reported to have lower rates of dating boys and being part of a sports team.  
The results of studies examining the prevalence of PCOS in lesbian women and heterosexual 
women are contrasting. For example, Smith et al. [74] did not find a difference in the 
prevalence of PCOS and associated factors (e.g. hirsutism and testosterone level) in a 
general population of lesbian and heterosexual women. In contrast, another study 
conducted in a clinical population found a significant higher prevalence of PCOS and 
associated factors in lesbian than in heterosexual women [75].  
Finally, one study found that higher testosterone levels and a higher incidence of hirsutism, 
acne, menstrual irregularities as well as a higher prevalence of PCOS in female-to-male 
transsexuals (FMT) [76].  
5. Part II 
The objective of Part II was to evaluate the association between PCOS characteristics 
(polycystic ovaries, hirsutism, acne, menstrual irregularities (amenorrhea and 
oligomenorrhea), and BMI) and endocrine variables (e.g., testosterone and estradiol) on the 
one hand and sexual well-being on the other hand. In addition, we studied whether there is 
an association between aspects of psycho-social well-being (self-esteem, body satisfaction, 
and self-perceived fear of negative appearance evaluation) and sexual well-being. 
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6. Methods 
6.1 Participants and procedure 
Women with normogonadotropic anovulation (WHO II) who attended our fertility clinic at 
the Erasmus MC University Medical Centre between 1991 and 2006 were included in this 
cross-sectional study. In this group of WHO II women, we determined if the diagnosis of 
PCOS could be established on the basis of the revised Rotterdam criteria [77]. To establish 
the diagnosis of PCOS, all patients underwent a standardized evaluation including: 
assessing cycle history, the presence or absence of acne, transvaginal ultrasonography (to 
assess ovarian volume and follicle count for both ovaries), and anthropomorphometric 
measurements (height and weight, Ferriman-Gallwey score). Exclusion criteria included the 
presence of related disorders with similar clinical presentation, such as congenital adrenal 
hyperplasia and Cushing’s syndrome. The study protocol was approved by the Medical 
Ethics Committee of the Erasmus MC University Medical Centre, Rotterdam the 
Netherlands. All patients gave informed consent prior to their inclusion in the present 
study. In 2007, all women with WHO II received a letter with information about the current 
study and a seventy-two item questionnaire. Two months after mailing this questionnaire, 
non-respondents were sent a reminder together with a copy of the questionnaire. 
6.2 Study outcomes 
6.2.1 Independent variables: PCOS characteristics and endocrine variables 
In the period of 1991 to 2006, all women who were referred to the fertility clinic underwent a 
standard fertility test including evaluation of the following aspects:  
1. Menstrual irregularities: oligomenorrhoea was defined as an interval between 
menstrual periods 35 days and amenorrhoea as the absence of vaginal bleeding for at 
least 6 months, i.e. >199 days;  
2. Biochemical and clinical hyperandrogenism: in accordance with the revised Rotterdam 
criteria, hyperandrogenism was defined as having either biochemical or clinical signs of 
androgen excess. Biochemical hyperandrogenism was defined by a free androgen index 
(FAI)>4.5. Clinical hyperandrogenism (hirsutism) was assessed by the Ferriman-
Gallwey score where patients estimated their hair growth on nine different body parts 
from 0 (no terminal hair) to 4 (maximal growth) with a maximum score of 36. A score of 
8 or more indicates the presence of hirsutism [78];  
3. Acne: the presence or absence of acne was evaluated by the physician;  
4. Polycystic ovaries (PCO): the presence of PCO was examined by vaginal ultrasound 
examination. PCO were defined as the presence of 12 follicles or more in one or both 
ovaries and/or increased ovarian volume (>10 ml); and 
5. Endocrine evaluation: blood samples were obtained by venipuncture. Serum levels of 
gonadotropic hormones (luteinizing hormone (LH) and follicle-stimulating hormone 
(FSH)), estradiol (E2), androgens (testosterone (T), androstenedione (AD), 
dehydroepiandrosterone (DHEA), and dehydroepiandrosterone sulphate (DHEAS)), 
progesterone, sex hormone-binding globulin levels (SHBG), fasting glucose and insulin, 
thyroid-stimulating hormone (TSH), and prolactin were obtained. Serum was isolated 
after centrifugation at 3000 rpm for 10 min at 20°C and subsequently stored at -20°C. 
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Immunofluorometric assays were used for the LH, FSH, TSH, prolactin and insulin, 
whereas serum E2, T, AD, and SHBG were measured by RIA provided by Diagnostic 
Products Corp. (Los Angelas, CA). Intraassay and interassay coefficients of variation 
were <5% and <15% for LH, <3% and <5% for T, <8% and <11% for AD, <5% and <7% 
for E2, <4% and <5% for SHBG, respectively [3]. 
6.2.2 Independent variables: Psycho-social well-being 
6.2.2.1 Rosenberg Self-Esteem Scale (RSES) 
The RSES was administered to measure the level of self-esteem. On a 4-point-Likert scale 
from ‘strongly disagree’ to ‘strongly agree’, responses on 5 positively worded and 5 
negatively worded questions were assessed. Higher scores reflect a higher level of self-
esteem. The Dutch version of the RSES was shown to have good internal reliability 
(Chronbach’s alpha = .87) [79].  
6.2.2.2 Body Cathexis Scale (BCS) 
The BCS is a self-report questionnaire assessing body satisfaction [80]. The questionnaire 
consists of 52 items about a person’s satisfaction with their body parts and body 
functions, such as hips and respiration. Body satisfaction is measured on a 5-point Likert 
scale from the most negative attitude towards a body part or function to the most positive 
attitude towards the body part or function. The Dutch version of the questionnaire was 
shown to have good test-retest reliability (Pearson product-moment correlation coefficient 
= .91) [81].  
6.2.2.3 Fear of Negative Appearance Evaluation Scale (FNAES) 
The brief version of the FNAES was used to assess apprehension related to a negative 
appearance evaluative experience. The items are answered on 5-point Likert scales from ‘not 
at all’ to ‘enormously’. The higher the score, the more fear of negative appearance 
evaluation by others is experienced. This six-item questionnaire was shown to be valid and 
reliable with a high internal consistency (Chronbach’s α=0.87) [82] 
6.2.3 Dependent variables: Sexual well-being 
6.2.3.1 Sexual well-being 
Subjects completed questions that were part of a Dutch questionnaire measuring sexual 
health in youth and young adults between the age of 12 and 25 years [83]. The questions that 
we used in the current study included the following: (1) ‘How old were you when you had your 
first intercourse?’; (2) ‘Have you ever had a romantic relationship?’; (3) ‘How old were you when you 
had your first romantic relationship?’; (4) ‘Have you ever been in love?’; and (5) Are you in a 
romantic relationship at this moment?’  
6.2.3.2 Confounders: Demographics 
Information on women’s demographic characteristics such as age and ethnicity were 
collected. Ethnicity was divided into two categories: (0) non-Caucasian (another ethnicity 
than Dutch) and (1) Caucasian (Dutch). 
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7. Statistical analyses 
Data are presented for women with PCOS only. As measures for central tendency the means 
(for continuous data) and medians (for ordinal data) were estimated, while as measure for 
dispersion standard deviation was used. The observed score range was also presented. To 
explore the association between sexual well-being variables (dependent variables) on the one 
hand and the PCOS characteristics and endocrine variables or psycho-social well-being 
(independent variables) on the other hand, multiple linear regression analysis was applied on 
continuous dependent variables. The PCOS characteristics and endocrine variables were 
entered into the regression analysis together with confounding variables (age and ethnicity). 
Psychological variables were analyzed separately. For dichotomous dependent variables, 
adjusted odds ratios (Ors) and 99% confidence intervals (CI) were derived from logistic 
regression analyses. PCOS characteristics were entered as dichotomous variables: 
oligoamenorrhoea (0) versus amenorrhoea (1); no or doubtful hirsutism (0) versus hirsutism 
(1); few or no acne (0) versus acne (1); no PCO (0) versus PCO (1). In analyzing the relationship 
between sexuality and PCOS characteristics, we adjusted for the time interval between the 
date of the clinical evaluation and the sexuality measures, age of the participant, and ethnicity. 
As sexarche was prior to the clinical investigation for most women, we entered years between 
sexarche and the clinical evaluation as a confounding variable in the analyses. Ethnicity was 
entered as a confounding variable because non-Caucasian women appeared to have sexarche 
later in life and higher clinical scores such as hirsutism than Caucasian women. Statistical 
analyses were performed using the Statistical Package for the Social Sciences (SPSS version 
15.0) and testing took place at a 0.05 level of significance (two tailed).  
8. Imputation 
Multiple imputation was performed using the SPSS software in the Missing Value Analysis 
module in SPSS (version 17.0) to impute missing values under missing-at-random 
assumptions and the reasons for the missing data are unrelated to the outcome [84]. 
Multiple imputed data sets of the data were created and replaced by imputed values based 
on estimated underlying distributions using the Expectation Maximization method [85]. 
Eight variables were imputed, of which six variables had ≤ than 1.5% imputed data. The 
variable acne (68%) and hirsutism (35%) had a high percentage of imputed data, numbers of 
missings that are controversy to impute.  
9. Results 
9.1 Participants 
In the period between 1991 and 2006, 1148 WHO II patients attended the fertility clinic of the 
Erasmus MC University Medical Centre and underwent standard clinical and endocrine 
evaluation. Of the 1148 women with WHO II, 480 women with PCOS returned the 
questionnaire. The overall participation rate was 51% of whom 42% had PCOS. Table I 
shows the demographical, clinical, endocrine, psychological, and sexual characteristics of 
the responders with PCOS in our study. It has been indicated that a higher percentage of 
non-responders with PCOS were overweight or obese and had hyperandrogenism 
compared to the responders [40]. In addition, we showed that PCOS women had lower self-
esteem and poorer body satisfaction compared to norm scores. Of the women that 
completed the sexuality questions, 2.1% responded that they had their first sexual 
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intercourse when they were of the age of 13 years or younger and 4.0% had their first 
relationship when they were13 years or younger. 
 
PCOS responders 
(n=480) 
Demographical characteristics
Age in years at date of clinical evaluation 28.8 (4.3), 14.2-40.0 (480) 
Caucasian 72.1% (346/480) 
Clinical 
Oligoamenorrhoea 71.7% (344/480) 
Amenorrea 28.3% (136/480) 
Presence of hirsutism  
Acne 
PCO 
31.9% (99/310) 
11% (17/154) 
92.5% (444/480) 
Body Mass Index (BMI kg/m²) 26.4 (6.0) [16.8-50.6] (479) 
BMI ≥ 25 (kg/m²) 48.6% (233/479) 
Endocrine 
Hyperandrogenism (FAI>4.5) 53.1% (255/480) 
LH 7.2 (5.6) [1.0-37.9] (480) 
FSH 4.9 (1.9) [1.1-10.5] (480) 
Progesterone 5.1 (10.1) [0.1 – 73.0] (479) 
SHBG 49.2 (33.3) [7.7 – 342] (480) 
T 2.2 (1.0) [0.3 – 6.7] (480) 
E2 275.8 (159.9) [51.0 – 1141.0] 
AD 13.0 (5.7) [2.6 – 40.7] 
DHEAS 6.0 (3.2) [0.2 – 21.3] 
Psycho-social well-being
RSES 31.0 (5.4) [14.0-40.0] (477) 
BCS 188.6 (30.3) [72.0 – 260.0] (435) 
FNAES 13.8 (5.9) [6.0 – 30.0] (473) 
Sexual well-being
‘Are you in a romantic relationship at this moment?’ %yes 92.7% (443/478) 
‘Have you ever been in love?’
% Never or 1 time 14.4% (69/473) 
% More than 1 time 84.2% (404/473) 
‘Have you ever had a romantic relationship?’ 
% Never or 1 time 41.6% (198/478) 
% More than 1 time 58.3% (280/478) 
‘How old were you when you had your first intercourse?’ 18.4 (3.3) [5.0 – 30.0] (467) 
‘How old were you when you had your first romantic 
relationship?’ 
17.7 (3.2) [10.0 – 30.0] (471) 
PCO= Polycystic ovaries; LH= luteinizing hormone; FSH= follicle-stimulating hormone; SHBG= sex 
hormone-binding globulin levels; DHEAS= dehydroepiandrosterone sulphate; T= Testosterone; E2= 
Estradiol; AD= Androstenedione; RSES= Rosenberg Self-esteem Scale; BCS= Body Cathexis Scale; 
FNAES= Fear of Negative Appearance Evaluation Scale. 
¹Values are mean (SD), range, N or (N/total N), or number (%) of participants. 
Table 1. Demographical and (bio)clinical characteristics of PCOS responders¹ 
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9.2 PCOS characteristics and endocrine variables and the association with sexual 
well-being  
Table II shows the regression coefficients (B’s) and corresponding P-values derived by the 
logistic and linear multivariate regression analyses studying the association between the 
dependent sexual well-being variables and independent PCOS symptoms and endocrine 
variables. 
Relationship at the moment 
Results indicated that oligomenorrhoea was positively associated with having a relationship 
at the moment. In addition, the confounder ethnicity was also significant. These results 
indicated that PCOS women with oligomenorrhoea were more likely than women with 
amenorrhea to have a relationship at the moment. In addition, Caucasian PCOS women 
were more likely to have a relationship at the time of questionnaire completion than non-
Caucasian PCOS women.  
In love 
Older PCOS women, Caucasian women, and women without or doubtful hirsutism were 
more likely to have been in love multiple times as compared to younger PCOS women. 
Relationship in the past 
The results showed that the confounders ethnicity, age, and the years between measuring 
the clinical/endocrine variables and sexuality variables were significant in logistic analysis: 
Caucasian women and older women were more likely to have had more than one 
relationship in the past. 
Age at first intercourse 
Non-Caucasian women and older women have had their first intercourse at an older age 
than younger and Caucasian PCOS women.  
Age at first relationship 
With respect to the age of the first relationship, we found women with PCOS and hirsutism 
and older women with PCOS were comparatively older when they had their first 
relationship. In addition, non-Caucasian women had their first relationship at an older age 
compared to Caucasian women.  
 DEPENDENT VARIABLES  
 Relationship at 
the moment
In love Relationship in 
the past
Age first 
intercourse 
Age first 
relationship 
Logistic 
regression 
B; P-value;
odds 
B; P-value;
odds 
B; P-value;
odds 
Multiva-
riate 
regression
B; P-value B; P-value 
PCO -1.33; 0.44
0.26
0.85; 0.55;
2.33
-0.12; 0.81;
0.89
-0.00; 1.00 -0.02; 0.97 
Cycle 
disturbances 
-0.99; 0.04*;
0.37
-0.24; 0.49;
0.79
-0.24; 0.30;
0.79
-0.26; 0.45 -0.12; 0.72 
Acné 2.01; 1.00;
7.48
4.69; 1.00;
108.83
-0.52; 0.42;
0.59
0.21; 0.75 0.38; 0.53 
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 DEPENDENT VARIABLES  
 Relationship at 
the moment
In love Relationship in 
the past
Age first 
intercourse 
Age first 
relationship 
Hirsutism -0.94; 0.10;
0.39
-1.17; 0.009*;
0.31
-0.43; 0.14;
0.65
0.79; 0.07 1.29; 0.002* 
BMI 0.07; 0.16;
1.07
0.01; 0.79;
1.01
0.00; 0.82;
1.00
-0.04; 0.12 -0.04; 0.17 
T 0.30; 0.40;
1.35
0.20; 0.38;
1.22
0.22; 0.15;
1.25
0.02; 0.94 -0.16; 0.44 
E2 0.00; 0.59;
1.00
0.00; 0.81;
1.00
0.00; 0.19;
1.00
0.00; 0.38 -0.00; 0.13 
Progesterone -0.02; 0.43;
0.98
-0.01; 0.45;
0.99
-0.01; 0.32;
0.99
0.02; 0.33 0.02; 0.14 
AD 0.08; 0.24;
1.09
0.03; 0.48;
1.03
0.04; 0.13;
1.04
0.00; 0.97 -0.02; 0.61 
SHBG 0.01; 0.26;
1.01 
-0.00; 0.77;
1.00 
0.00; 0.92;
1.00 
0.00; 0.68 0.01; 0.13 
DHEAS -0.07; 0.39;
0.93
0.02; 0.73;
1.02
0.01; 0.79;
1.01
0.03; 0.64 0.04; 0.48 
Age 0.08; 0.12;
1.08
0.10; 0.01*;
1.10
0.08; 0.003*;
1.08
0.17; 0.000* 0.12; 0.001* 
Yrs between 
sexarche and 
clinical 
evaluation 
-0.12; 0.07  
Ethnicity -1.35; 0.008*;
0.23
-1.13; 0.001*;
0.32
-0.56; 0.02*;
0.57
1.73; 0.000* 1.56; 0.000* 
Yrs between 
sexual 
variables 
and clinical 
evaluation 
0.00; 1.00;
1.00 
-0.23; 0.001*;
0.79 
-0.16; 0.000*;
0.85 
-0.14; 0.027* 
PCO= Polycystic ovaries; BMI= Body Mass Index; T= Testosterone; E2= Estradiol; AD= 
Androstenedione; SHBG= sex hormone-binding globulin levels; DHEAS= dehydroepiandrosterone 
sulphate. 
*Significant at a 0.05 level of significance 
Table 2. The association between the dependent sexual well-being variables and 
independent PCOS symptoms and endocrine variables 
9.3 Psycho-social well-being and the association with sexual well-being 
Table III shows the regression coefficients (B’s) with corresponding P-values derived by the 
logistic and linear multivariate regression analyses analyzing the association between the 
dependent sexual well-being variables and independent psycho-social well-being variables. 
Relationship at the moment 
In logistic regression analysis studying the association between having a relationship at the 
moment and psycho-social variables, we found that older PCOS women and Caucasian 
women were more likely to have a relationship at the moment than younger and non-
Caucasian PCOS women.  
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In love 
PCOS women with higher self-esteem and Caucasian women were more likely to have been 
in love multiple times.  
Relationship in the past 
Being Caucasian, having higher self-esteem and lower body satisfaction scores were 
associated with having had multiples relationship in the past. 
Age at first intercourse 
Being older and non-Caucasian were both associated with having experienced the first 
intercourse at an older age. 
Age at first relationship 
Finally, PCOS women with lower levels of self-esteem as well as women with greater body 
satisfaction had their first relationship at an older age. Also, both older women with PCOS 
and non-Caucasian PCOS women were more likely to be comparatively older when they 
had their first relationship. 
 DEPENDENT VARIABLES  
 Relationship 
at the 
moment
In love Relationship 
in the past 
Age first 
intercourse 
Age first 
relationship 
Logistic 
regression 
B; P-value;
odds 
B; P-value;
odds 
B; P-value;
odds 
Multivariate 
regression 
B; P-value;
 
B; P-value; 
 
RSES 
 
0.08; 0.07;
1.08 
0.10; 0.003*;
1.10 
0.06; 0.02*;
1.01 
-0.06; 0.15 -0.09; 0.02* 
BCS -0.01; 0.30;
0.99 
-0.01; 0.11;
0.99 
-0.01; 0.04*;
1.00 
0.01; 0.17 0.02; 0.01* 
FNAES -0.01; 0.84;
0.99
0.05; 0.09;
1.05
0.03; 0.22;
1.03
-0.02; 0.60 0.00; 0.97 
Age 
 
0.08; 0.02*;
1.08
0.01; 0.76;
1.01
0.01; 0.51;
1.01
0.12; 0.000* 0.08; 0.004* 
Ethnicity -1.13; 0.002*;
0.32
-1.21; 0.000*;
0.30
-0.53; 0.01*;
0.59
1.75; 0.000* 1.57; 0.000* 
RSES= Rosenberg Self-esteem Scale; BCS= Body Cathexis Scale; FNAES= Fear of Negative Appearance 
Evaluation Scale. 
*Significant at a 0.05 level of significance 
Table 3. The association between the dependent sexual well-being variables and 
independent psycho-social well-being variables 
10. Discussion 
A higher incidence of psycho-social disturbances [8] and impaired sexual well-being [7, 26, 
65] in women with PCOS highlight the clinical relevance of these topics. To improve overall 
well-being in women with PCOS, we need to have a better understanding to what extent the 
features of the syndrome affect psycho-social and sexual well-being.  
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The current study examined the association of PCOS characteristics and endocrine variables 
with sexual well-being. In addition, we studied whether psycho-social well-being was 
associated with sexual health. First, we found that several PCOS characteristics and 
endocrine parameters predicted sexual well-being. PCOS women with amenorrhoea seem to 
be less likely to have had a relationship at the time of completing the questionnaire. It is 
imaginable that an irregular cycle causes distress in women, which might have withheld 
them from starting a romantic relationship. In the same line, it has been found that 
menstrual irregularities decrease QoL [7] and are linked to fear of negative appearance 
evaluation [40]. An association between menstrual irregularities and any aspect of sexual 
health has not been confirmed previously [7].  
Furthermore, we found that women with PCOS and hirsutism were less likely to have been 
in love more than once and were older when they had their first relationship. It is widely 
recognized that hirsutism is one of the many factors that has a considerable negative impact 
on QoL [21], self-esteem, body satisfaction [5, 35, 40], and sexual health [23]. Hirsutism is 
considered as one of the most stressful characteristics of PCOS [10]. As women with PCOS 
and hirsutism also experience greater fear of negative appearance evaluation [40] and 
excessive body hair seem to withhold PCOS women from making social contacts [7], it 
seems plausible to assume that this negatively affects starting a romantic relationship.  
With respect to the studied endocrine variables, we did not find that hormonal and 
endocrine variables are associated with sexual health. In contrast, other studies showed that 
higher levels of T and androgens are associated with higher levels of sexual arousal and 
sexual desire [54, 66, 86], although an association with DHEAS was not confirmed in a 
previous study [58]. However, we measured different aspects of sexual well-being. Other 
studies showed decreased lubrication [66], lower levels of arousal, and improvement of 
orgasm frequency by using oral contraceptives [60]. Furthermore, lower levels of T seem to 
be associated with depression [42], which might also have indirectly influenced sexual well-
being. Contrasting results have been found with respect to sexual desire in PCOS women 
[66, 69, 87]. Anti-androgen therapy seems to further lower sexual desire, even though it 
improved psychological well-being [68]. Contrasting results with respect to the association 
between androgens and sexual desire [66, 69, 87] indicate that androgen levels are as yet 
unreliable predictors of sexual functioning, specifically for sexual desire. It is hypothesized 
that contradicting findings concerning the role of androgens in female sexual functioning 
may be due to, among other factors, a greater variety in responsiveness to testosterone in 
women and mediation of psychological mechanisms [61]. 
With respect to the significant result of the confounder age, it is imaginable that older 
women have different norms and values concerning sexuality and romantic relationships. 
For example, it is not inconceivable that the age of having first sexual intercourse or a 
relationship is younger in the present time than in previous generations. In addition, the 
confounder ethnicity is also associated with sexual well-being. Possible differences in sexual 
morality and cultural backgrounds might have caused non-Caucasian women to have their 
first intercourse at an older age.  
Surprisingly, BMI and acne were not found to predict any of our measured sexual well-
being variables. We might have failed to find an effect for acne since this variable had much 
missing data. Imputing high percentages of missing data is controversial; however, when 
we analyzed the data again on non-imputed data. The results still indicated a non-
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significant effect of acne. Also, Progesterone, SHBG, and E2 were not related to sexual health 
in the current study.  
Second, we studied the association between psycho-social variables and sexual health. 
Women with PCOS seem to have poorer self-esteem and poorer body satisfaction compared 
to the general population [40]. In addition, it is indicated that PCOS characteristics such as 
hirsutism, menstrual irregularities, and BMI are related to impaired psychological 
functioning [40]. In the current study, we demonstrated that self-esteem plays a significant 
role in sexual health. We showed that PCOS women with greater self-esteem are more likely 
have been in love multiple times, to have had more than one relationship in the past, and to 
have their first relationship at a younger age compared to PCOS women with poorer self-
esteem. Decreased sexual satisfaction has been reported in PCOS women [7, 26, 65, 66], 
which is negatively correlated to BMI and hirsutism. Improving hirsutism and acne, for 
instance by using an oral contraceptive, seem to improve sexual satisfaction, sexual 
attractiveness, and self-esteem [60, 68, 71]. Furthermore, an improvement in QoL seems to 
be related to an increase in the frequency of sexual intercourse and satisfaction with sex life 
in women with PCOS [7, 65]. Also, it has been shown that BMI, hirsutism, acne negatively 
influences making social contacts in women with PCOS [61], probably due to low self-
esteem. Therefore, it seems conceivable that women with higher levels of self-esteem feel 
more confident to make social contact and specifically start romantic relationships. 
Surprisingly, we found that women with greater body satisfaction were older when they 
had their first relationship. Likewise, it is indicated that body dissatisfaction increased the 
probability of coitus onset in adolescent girls [88]. Future research should further investigate 
this relationship. Fear of negative appearance evaluation was not related to any of the sexual 
variables. This is surprising as it would be plausible to assume that if a person fears what 
others think of their appearance, they are less likely to be involved in romantic relationships. 
A recent study indicated that increased anxiety predicted lifelong female sexual 
dysfunctioning in a sample of the general population [89]. Future research should focus on 
the relation of anxiety and sexual health in women with PCOS.  
Pitfalls of studies conducting research on psycho-social and sexual well-being in women 
with PCOS include the use of self-reported measures. Self-reported questionnaires measure 
mostly mental symptoms but not clinical syndromes. Mansson et al. [8] did use clinical 
structured interviews to assess DSM-IV diagnoses and did show psychiatric disorders such 
as depression and anxiety to be more common in women with PCOS compared to controls. 
Other drawbacks of our study include that the PCOS women completed the questionnaires 
later in time than the laboratory and clinical tests were performed. Patients reasonably 
would have scored the psychological questionnaires different at the time when laboratory 
and clinical parameters were measured and reported to them. Therefore, we also adjusted 
for the time interval in years between the endocrine evaluation and the psychological 
measures. Furthermore, we did not include a matched control group. The current results 
therefore particularly apply to differences within the PCOS population. Finally, the non-
responding rate in our study was high [40]. This might be due to a high percentage of non-
Caucasian patients in the non-responding group. A possible explanation is that the 
Caucasian non-responders had trouble filling out the questionnaires due to insufficient 
command of the Dutch language. Therefore the results could not be generalized to all 
women with PCOS. Furthermore, it might be that those women returning the questionnaire 
were those PCOS women whose psycho-social and sexual well-being were the least affected 
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by their syndrome. In the latter case, the impact of PCOS on psycho-social and sexual well-
being might even be underestimated. The impact of symptoms of PCOS on sexual well-
being established in the current study might also be underestimated because the non-
responders harboured the more pronounced phenotypes.  
In conclusion, this study stresses that the treatment of women with PCOS should notably 
focus not only on physical but also on psycho-social and sexual well-being. Future research 
should study various aspects of sexuality, e.g. sexual satisfaction, sexual motivation, and 
sexual self-esteem in randomized control trials with validated questionnaires as well as the 
influence of PCOS features. To fully understand the correlation between PCOS and 
sexuality, future studies should take all confounders (endocrine, psychological, and 
interpersonal) into account. 
11. Clinical management  
The overview provided in this chapter demonstrates the considerable impact of PCOS and 
its symptoms on psycho-social and sexual health. As women with PCOS are four times more 
likely to have abnormal depression scores compared to controls [90] This risk was 
independent of BMI, therefore it seems necessary to screen all women with PCOS for 
depression using validated measurements. Moreover, the literature shows an impairment of 
a variety of psycho-social and sexual health domains in women with PCOS and associations 
with features of PCOS characteristics. Therefore, we recommend assessing psycho-social 
and sexual domains by validated measurements.  
An important finding is that treatment of associated PCOS characteristics seems to improve 
psychological and sexual outcomes. For example, metformin or oral contraceptive pill 
treatment in women with PCOS seems to be related to a reduction of clinical symptoms as 
well as to an improved psychological and sexual well-being [65]. In addition, using an oral 
contraceptive [60] or metformin [65] seems to decrease the frequency of painful intercourse. 
A reduction in body weight and normalized menstrual cycle seems to have mediated these 
findings. Various oral contraceptives seem to have a different effect on sexuality and 
psychosocial factors [60, 68, 91]. This should be taken into account when prescribing these 
medications. 
Furthermore, the presence of obesity in PCOS women is associated with various physical 
consequences and psychological impairments. Lifestyle modification should be the first step 
before treating PCOS women for their infertility. Various studies have investigated the 
effects of weight loss and weight loss interventions in women with PCOS, indicating the 
beneficial effects of weight loss on the clinical and biochemical manifestations of PCOS [92, 
93], insulin sensitivity [94], and menstrual cyclicality and fertility outcomes during 
treatment [95, 96]. Moreover, self-esteem [95] and quality of life [97] have found to be 
improved by modest weight loss of 5% to 10% of the initial body weight. We also discussed 
the considerable impact of hirsutism on several psychosocial and sexual domains. It has 
been shown that laser treatment aimed at reducing the severity of facial hirsutism has not 
only a positive effect on the severity of facial hair, but also seems to improve self-esteem and 
QoL [98] and alleviate depression and anxiety [99]. Therefore, treatment of related PCOS 
symptoms should be considered. 
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A recent paper of Farrell and colleagues [37] demonstrated the benefits of psychological and 
behavioural approaches in addition to medical management of PCOS. Likewise, Rofey et al. 
[38] found decreased depression scores as well as weight loss after a behavioural program in 
adolescents with PCOS. The intervention consisted of phone calls and face to face meetings 
addressing coping mechanisms, scheduling behaviourally activating events, and engaging 
in positive thinking and cognitive restructuring. Furthermore, another study showed that a 
nurse-led peer support group providing socio-emotional and informational support reduced 
isolation and women reported feeling empowered [100].  
Bitzer et al. [101] developed a tool for sexual counselling that can be used by physicians. It 
contains 3 dimensions (pre-existing person related factors, disease specific factors, and the 
individual’s and partners reaction to the disease) that can be addressed when discussing 
sexuality with the patient. Remembering these dimensions is fairly easy and gives a good 
direction in discussing sexuality aspects with patients. A treatment plan might depend on 
the outcome of the conversation. Another easy-to-use tool is the PLISSIT model [102]. This is 
a stepped care model providing guidance in counselling and treating sexual problems.  
Aforementioned treatments and their positive effect on psycho-social and sexual well-being 
indicate that physicians should work interdisciplinary to also address consequences other 
than physical consequences and discuss treatment options aimed at reducing PCOS 
characteristics and improving psycho-social and sexual well-being.  
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